METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANYING METABOLIC SYNDROME Russian patent published in 2019 - IPC A61M21/00 A61K31/155 A61K31/185 A61K31/575 A61P1/16 G01N33/48 

FIELD: medicine.

SUBSTANCE: invention refers to therapy and hepatology, and can be used for treating non-alcoholic fatty liver disease accompanying metabolic syndrome. That is ensured by administering ursodeoxycholic kilo in dose of 15 mg/kg for 6 months if the transaminase level is more than three. Additionally, diet therapy is performed within 12 months with restriction of fats and usage of carbohydrate-containing products with glycemic index less than 70, at that reducing caloric content of ration by 500 kcal from initial one. Minimum calorie intake per day shall be not less than 1,200 kcal for women and not less than 1,500 kcal for men. Additionally, the HOMA-IR insulin resistance index is calculated. If HOMA-IR is more than 2.7 Glucophage® Long 1,000 mg is prescribed in the evening after lunch for 12 months. That is followed by determining ferritin level in blood serum. If the ferritin value is 60 mcg/l and higher, Thiogam 600 mg is prescribed for 3 months, then in dose of 300 mg for following 3 months.

EFFECT: method provides reduced hepatic steatosis, reduced degree of abdominal obesity and metabolic disorders ensured by the hepatoprotective effect of the therapy, higher tissue sensitivity to insulin, reduced transaminase ACT, ALT and lipids, namely total cholesterol, low-density lipoprotein cholesterol and triglycerides.

1 cl, 3 tbl, 1 ex